Drug intelligence / Profile preview

aripiprazole + quetiapine

Development stage: Unknown
Lead developer: Taiho Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

A combination of two atypical antipsychotic medications. Aripiprazole acts as a partial agonist at dopamine and serotonin receptors, while quetiapine functions as an antagonist at these receptors. This combination is generally considered pharmacologically irrational due to overlapping effects and increased risk of side effects.

Targets

DRD4 (Dopamine D4 Receptor)HTR2A (Serotonin receptor 5-HT2A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2C (5-hydroxytryptamine 2C receptor)HRH1 (Histamine H1 Receptor)ADRA1A (α1A)SERT (Sodium-dependent serotonin transporter)ADRA2A (α2A)HTR2B (5-Hydroxytryptamine Receptor 2B)DRD2 (Dopamine D2 Receptor)HTR7 (5-hydroxytryptamine receptor 7)DRD3 (Dopamine receptor D3)

Beyond the preview

Go deeper on aripiprazole + quetiapine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aripiprazole + quetiapine.

Explore the full profile